Personalized Recommendations for AKI Using a Kidney Action Team: A Multicenter Randomized Controlled Trial
Aklilu A, Menez S, Yamamoto Y, Bitzel J, Villalobos C, O'Connor K, Shelton K, Faulkner S, Makhijani A, Kadhim B, Parikh C, Wilson F. Personalized Recommendations for AKI Using a Kidney Action Team: A Multicenter Randomized Controlled Trial. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024gjjnbwvc. DOI: 10.1681/asn.2024gjjnbwvc.Peer-Reviewed Original ResearchMulticenter randomized controlled trialRandomized controlled trialsRationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis
Barsotti G, Luciano R, Kumar A, Meliambro K, Kakade V, Tokita J, Naik A, Fu J, Peck E, Pell J, Reghuvaran A, Tanvir E, Patel P, Zhang W, Li F, Moeckel G, Perincheri S, Cantley L, Moledina D, Wilson F, He J, Menon M. Rationale and Design of a Phase 2, Double-blind, Placebo-Controlled, Randomized Trial Evaluating AMP Kinase-Activation by Metformin in Focal Segmental Glomerulosclerosis. Kidney International Reports 2024, 9: 1354-1368. PMID: 38707807, PMCID: PMC11068976, DOI: 10.1016/j.ekir.2024.02.006.Peer-Reviewed Original ResearchMinimal change diseaseRandomized controlled trialsSafety of metforminDouble-blindPodocyte injuryAdjunctive therapyPlacebo-controlled randomized controlled trialsPhase III studyPhase II trialPrimary glomerular diseaseFocal segmental glomerulosclerosisEffect of metforminPhase IIPlacebo-controlledPreclinical dataNovel urineChange diseaseTissue markersRandomized trialsSegmental glomerulosclerosisGlomerular diseaseMechanistic biomarkersObservational studyFSGSInexpensive agent